Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) - Net Assets

Latest as of June 2026: CN¥2.32 Billion CNY ≈ $339.12 Million USD

Based on the latest financial reports, Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) has net assets worth CN¥2.32 Billion CNY (≈ $339.12 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.71 Billion ≈ $688.58 Million USD) and total liabilities (CN¥2.39 Billion ≈ $349.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tonghua Golden-Horse Pharmaceutical Indu PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥2.32 Billion
% of Total Assets 49.25%
Annual Growth Rate 8.74%
5-Year Change -1.23%
10-Year Change -44.48%
Growth Volatility 192.63

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd - Net Assets Trend (1994–2025)

This chart illustrates how Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 000766 market cap.

Annual Net Assets for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (1994–2025)

The table below shows the annual net assets of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd from 1994 to 2025. Also explore 000766 net asset momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 CN¥2.31 Billion
≈ $338.09 Million
+2.44%
2024-12-31 CN¥2.26 Billion
≈ $330.04 Million
-2.71%
2023-12-31 CN¥2.32 Billion
≈ $339.21 Million
-2.13%
2022-12-31 CN¥2.37 Billion
≈ $346.59 Million
+1.25%
2021-12-31 CN¥2.34 Billion
≈ $342.31 Million
+1.47%
2020-12-31 CN¥2.31 Billion
≈ $337.34 Million
-13.53%
2019-12-31 CN¥2.67 Billion
≈ $390.12 Million
-43.38%
2018-12-31 CN¥4.71 Billion
≈ $689.06 Million
+6.57%
2017-12-31 CN¥4.42 Billion
≈ $646.57 Million
+6.18%
2016-12-31 CN¥4.16 Billion
≈ $608.95 Million
+85.25%
2015-12-31 CN¥2.25 Billion
≈ $328.72 Million
+240.62%
2014-12-31 CN¥659.50 Million
≈ $96.51 Million
+7.22%
2013-12-31 CN¥615.08 Million
≈ $90.01 Million
-0.73%
2012-12-31 CN¥619.60 Million
≈ $90.67 Million
+2.05%
2011-12-31 CN¥607.13 Million
≈ $88.84 Million
+1.89%
2010-12-31 CN¥595.89 Million
≈ $87.20 Million
+2.06%
2009-12-31 CN¥583.87 Million
≈ $85.44 Million
+5.38%
2008-12-31 CN¥554.08 Million
≈ $81.08 Million
+3.20%
2007-12-31 CN¥536.90 Million
≈ $78.57 Million
+3.63%
2006-12-31 CN¥518.07 Million
≈ $75.81 Million
+1044.65%
2005-12-31 CN¥45.26 Million
≈ $6.62 Million
+23.54%
2004-12-31 CN¥36.64 Million
≈ $5.36 Million
-87.63%
2003-12-31 CN¥296.07 Million
≈ $43.32 Million
-39.68%
2002-12-31 CN¥490.79 Million
≈ $71.82 Million
+3.31%
2001-12-31 CN¥475.05 Million
≈ $69.52 Million
-55.89%
2000-12-31 CN¥1.08 Billion
≈ $157.58 Million
+2.86%
1999-12-31 CN¥1.05 Billion
≈ $153.20 Million
+64.40%
1998-12-31 CN¥636.82 Million
≈ $93.19 Million
+5.63%
1997-12-31 CN¥602.89 Million
≈ $88.22 Million
+215.27%
1996-12-31 CN¥191.23 Million
≈ $27.98 Million
+5.47%
1995-12-31 CN¥181.32 Million
≈ $26.53 Million
+5.51%
1994-12-31 CN¥171.84 Million
≈ $25.15 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 9576.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Other Components CN¥4.56 Billion 197.21%
Total Equity CN¥2.31 Billion 100.00%

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Competitors by Market Cap

The table below lists competitors of Tonghua Golden-Horse Pharmaceutical Industry Co Ltd ranked by their market capitalization.

Company Market Cap
Schiehallion Fund Ltd
LSE:MNTN
$2.22 Billion
Hyperliquid Strategies Inc Common Stock
NASDAQ:PURR
$2.22 Billion
Margun Enerji Uretim Sanayi ve Ticaret AS
IS:MAGEN
$2.22 Billion
StoneCo Ltd
NASDAQ:STNE
$2.22 Billion
AtriCure Inc
NASDAQ:ATRC
$2.21 Billion
Imerys SA
PA:NK
$2.21 Billion
Prestige Brand Holdings Inc
NYSE:PBH
$2.21 Billion
Energa S.A.
WAR:ENG
$2.21 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,255,397,745 to 2,310,530,473, a change of 55,132,728 (2.4%).
  • Net income of 34,286,478 contributed positively to equity growth.
  • Dividend payments of 81,315,425 reduced retained earnings.
  • Other comprehensive income decreased equity by 666,945,997.
  • Other factors increased equity by 769,107,672.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥34.29 Million +1.48%
Dividends Paid CN¥81.32 Million -3.52%
Other Comprehensive Income CN¥-666.95 Million -28.87%
Other Changes CN¥769.11 Million +33.29%
Total Change CN¥- 2.44%

Book Value vs Market Value Analysis

This analysis compares Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 6.55x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 39.03x to 6.55x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-12-31 CN¥0.40 CN¥15.66 x
1995-12-31 CN¥0.42 CN¥15.66 x
1996-12-31 CN¥0.45 CN¥15.66 x
1997-12-31 CN¥1.36 CN¥15.66 x
1998-12-31 CN¥1.44 CN¥15.66 x
1999-12-31 CN¥2.39 CN¥15.66 x
2000-12-31 CN¥2.47 CN¥15.66 x
2001-12-31 CN¥1.10 CN¥15.66 x
2002-12-31 CN¥1.14 CN¥15.66 x
2003-12-31 CN¥0.69 CN¥15.66 x
2004-12-31 CN¥0.09 CN¥15.66 x
2005-12-31 CN¥0.11 CN¥15.66 x
2006-12-31 CN¥1.21 CN¥15.66 x
2007-12-31 CN¥1.14 CN¥15.66 x
2008-12-31 CN¥1.29 CN¥15.66 x
2009-12-31 CN¥1.37 CN¥15.66 x
2010-12-31 CN¥1.49 CN¥15.66 x
2011-12-31 CN¥1.62 CN¥15.66 x
2012-12-31 CN¥1.61 CN¥15.66 x
2013-12-31 CN¥1.50 CN¥15.66 x
2014-12-31 CN¥1.28 CN¥15.66 x
2015-12-31 CN¥3.27 CN¥15.66 x
2016-12-31 CN¥4.44 CN¥15.66 x
2017-12-31 CN¥4.59 CN¥15.66 x
2018-12-31 CN¥4.80 CN¥15.66 x
2019-12-31 CN¥2.72 CN¥15.66 x
2020-12-31 CN¥2.35 CN¥15.66 x
2021-12-31 CN¥2.39 CN¥15.66 x
2022-12-31 CN¥2.42 CN¥15.66 x
2023-12-31 CN¥2.64 CN¥15.66 x
2024-12-31 CN¥2.40 CN¥15.66 x
2025-12-31 CN¥2.39 CN¥15.66 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tonghua Golden-Horse Pharmaceutical Industry Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1.48%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 2.93%
  • • Asset Turnover: 0.26x
  • • Equity Multiplier: 1.94x
  • Recent ROE (1.48%) is above the historical average (-23.65%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 13.30% 22.98% 0.43x 1.36x CN¥5.67 Million
1995 25.85% 35.37% 0.46x 1.60x CN¥28.73 Million
1996 34.51% 40.27% 0.46x 1.85x CN¥46.87 Million
1997 16.34% 39.61% 0.31x 1.33x CN¥37.06 Million
1998 10.66% 24.24% 0.31x 1.41x CN¥4.06 Million
1999 7.94% 28.55% 0.21x 1.30x CN¥-21.06 Million
2000 22.90% 47.98% 0.22x 2.14x CN¥136.28 Million
2001 -123.68% -581.60% 0.07x 3.11x CN¥-631.35 Million
2002 3.36% 10.20% 0.11x 3.13x CN¥-32.45 Million
2003 -65.98% -141.91% 0.10x 4.89x CN¥-223.71 Million
2004 -670.58% -245.99% 0.09x 29.78x CN¥-249.34 Million
2005 18.73% 6.00% 0.13x 24.45x CN¥3.95 Million
2006 -1.65% -6.06% 0.18x 1.54x CN¥-60.37 Million
2007 3.51% 12.42% 0.19x 1.51x CN¥-34.86 Million
2008 3.10% 10.75% 0.20x 1.46x CN¥-38.23 Million
2009 5.10% 17.72% 0.19x 1.49x CN¥-28.60 Million
2010 2.02% 7.09% 0.19x 1.51x CN¥-47.57 Million
2011 1.85% 6.28% 0.20x 1.45x CN¥-49.47 Million
2012 0.62% 3.02% 0.14x 1.44x CN¥-58.10 Million
2013 0.67% 2.77% 0.13x 1.80x CN¥-57.42 Million
2014 0.78% 2.48% 0.16x 1.95x CN¥-60.78 Million
2015 0.31% 3.47% 0.05x 1.85x CN¥-217.77 Million
2016 5.18% 25.11% 0.16x 1.29x CN¥-198.83 Million
2017 5.89% 16.95% 0.27x 1.31x CN¥-180.20 Million
2018 7.08% 15.80% 0.35x 1.28x CN¥-136.42 Million
2019 -77.61% -103.27% 0.42x 1.79x CN¥-2.30 Billion
2020 -15.83% -32.33% 0.22x 2.19x CN¥-586.64 Million
2021 1.53% 2.33% 0.33x 2.01x CN¥-195.40 Million
2022 1.29% 2.05% 0.31x 2.00x CN¥-203.53 Million
2023 1.90% 2.98% 0.33x 1.95x CN¥-187.83 Million
2024 2.50% 4.27% 0.29x 1.99x CN¥-169.10 Million
2025 1.48% 2.93% 0.26x 1.94x CN¥-196.77 Million

Industry Comparison

This section compares Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,159,462,338
  • Average return on equity (ROE) among peers: 8.85%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) CN¥2.32 Billion 13.30% 1.03x $2.21 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $5.88 Billion 7.12% 1.83x $577.52 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $638.89 Million 0.88% 0.70x $407.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $793.34 Million 10.94% 0.24x $4.35 Billion
Livzon Pharmaceutical Group Inc (000513) $275.56 Million 21.50% 1.16x $2.29 Billion
Wedge Industrial Co Ltd (000534) $654.70 Million 1.92% 0.87x $1.74 Billion
Yunnan Baiyao Group Co Ltd (000538) $893.64 Million 25.78% 0.79x $13.25 Billion
Hainan Haiyao Co Ltd (000566) $1.49 Billion 5.19% 0.85x $861.90 Million
Tus Pharmaceutical Group Co Ltd (000590) $347.80 Million 3.58% 0.72x $308.02 Million
Northeast Pharmaceutical Group Co Ltd (000597) $869.73 Million 4.99% 1.99x $964.68 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $9.75 Billion 6.63% 0.12x $3.04 Billion

About Tonghua Golden-Horse Pharmaceutical Industry Co Ltd

SHE:000766 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.21 Billion
CN¥15.14 Billion CNY
Market Cap Rank
#5818 Global
#1082 in China
Share Price
CN¥15.66
Change (1 day)
+0.19%
52-Week Range
CN¥15.05 - CN¥29.50
All Time High
CN¥29.50
About

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive m… Read more